BioCentury
ARTICLE | Clinical News

Neurocrine soars after NBI-98854 meets in tardive dyskinesia trial

January 8, 2014 1:30 AM UTC

Neurocrine Biosciences Inc. (NASDAQ:NBIX) jumped $8.75 (87%) to $18.51 on Tuesday after reporting that once-daily oral NBI-98854 met the primary endpoint in 89 patients in the intent-to-treat (ITT) population of the Phase IIb Kinect 2 Study to treat tardive dyskinesia. NBI-98854 reduced mean Abnormal Involuntary Movements Scale (AIMS) score as determined by blinded central video assessment from baseline to week six vs. placebo (p<0.001). The double-blind, U.S. trial enrolled 102 patients with moderate to severe tardive dyskinesia and an underlying mood disorder, schizophrenia or schizoaffective disorder, or a gastrointestinal disorder. The ITT population included all patients who had an AIMS assessment at week six. Patients received placebo or once-daily NBI-98854 at an initial dose of 25 mg that could be titrated up to 75 mg.

Neurocrine is now above its share price of $16.70 on Sept. 9, before the company reported data from the Phase IIb Kinect Study showing once-daily 50 mg NBI-98854 missed the primary endpoint of reducing mean AIMS score as determined by either onsite or blinded central video assessment from baseline to week 6 vs. placebo. Neurocrine fell $4.96 (30%) to $11.74 on that data (see BioCentury Extra, Sept. 10, 2013). ...